Colorectal Cancer
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 69 Shown
  • Focus on Metastatic Colorectal Cancer: An Interactive Decision Support Tool

    This interactive treatment decision aid will let you compare your choice of therapy for patients with metastatic CRC with expert recommendations from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD, FACP; John Strickler, MD; and Alan P. Venook, MD.
    Date Posted: 10/17/2017
  • How I Manage Patients With Chemotherapy-Refractory Metastatic CRC

    John Strickler MD - 9/11/2017
    As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.
  • Then and Now: My Take on Individualizing Therapy for Progressive Colorectal Cancer in 2017

    John L. Marshall MD - 8/21/2017 12 comments / Last Comment: 10/18/2017
    Later-line treatment options for CRC have expanded markedly since 2015. How should we use established and emerging molecular markers in 2017 to select the optimal regimen for each patient?
  • Combination Therapy With BRAF Inhibitors: A New Frontier in BRAF-Mutant CRC

    Scott Kopetz MD, PhD, FACP - 8/14/2017 4 comments / Last Comment: 9/16/2017
    BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.
  • Learning Module cme-icon

    New Findings in Gastrointestinal Cancers

    In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.
    Faculty: Steven J. Cohen MD, Alan P. Venook MD
    Released: 8/7/2017
  • Testing for Microsatellite Instability in the Era of Immune Checkpoint Inhibitors

    John L. Marshall MD - 7/11/2017 3 comments / Last Comment: 8/8/2017
    Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.
  • At a Glance: Biomarkers of Response to Immune Checkpoint Inhibitor Therapy in Colorectal Cancer

    In this downloadable resource, expert faculty John L. Marshall, MD, reviews key testing methods for microsatellite instability, PD-L1, and other biomarkers of response to immune checkpoint inhibitors in patients with colorectal cancer. For additional in-depth analysis, please review the accompanying CME-certified text modules, downloadable slides, and ClinicalThought commentaries for expert guidance on the optimal use of immunotherapy in colorectal cancer.
    Date Posted: 6/26/2017
  • Downloadable Slides: Fighting a Smarter War on Colon Cancer

    In this downloadable slideset, John L. Marshall, MD, reviews the latest clinical data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Marshall’s expert in-depth discussion.
    Date Posted: 6/21/2017
  • Clinical Focus cme-icon

    Fighting a Smarter War on Colon Cancer: Immune Therapy in GI Cancers

    In this module, John L. Marshall, MD, reviews practice-changing immunotherapy options for patients with metastatic colorectal cancer, as well as biomarkers that predict response to immune checkpoint inhibitors and the latest data supporting their use in GI malignancies.
    Faculty: John L. Marshall MD
    Released: 6/21/2017
  • Immune Checkpoint Inhibitors: A Game Changer in GI Malignancies

    Tanios Bekaii-Saab MD, FACP - 6/21/2017 2 comments / Last Comment: 8/8/2017
    With the first immunotherapy agent approved for use in colorectal cancer, how is this going to change your practice?
10 of 69 Shown
Show 10 More
Loading...